Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
Sponsor
Pfizer (Industry)
Overall Status
Available
CT.gov ID
NCT05466578
Collaborator
In Expanded Access, treating physicians are the Sponsor (Other)
Study Details
Study Description
Brief Summary
Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Expanded Access requests from treating physicians may be submitted at www.pfizercares.com ; availability will depend on location/country.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
12 Years
and Older
Sexes Eligible for Study:
All
Must have severe uncontrolled atopic dermatitis refractory to other available treatments
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
- In Expanded Access, treating physicians are the Sponsor
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pfizer
ClinicalTrials.gov Identifier:
NCT05466578
Other Study ID Numbers:
- B745
First Posted:
Jul 20, 2022
Last Update Posted:
Jul 20, 2022
Last Verified:
Jun 1, 2022
Keywords provided by Pfizer
Additional relevant MeSH terms: